Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic methodologies: serology, endoscopy, and radiology

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

The two major inflammatory bowel diseases, Crohn’s disease (CD) and ulcerative colitis (UC), represent clinicopathologic entities that traditionally have been diagnosed on the basis of a combination of clinical, radiologic, endoscopic, and histologic features. Serum perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) have recently been added to our diagnostic armamentarium. Several studies have demonstrated that UC-associated pANCAs recognize nuclear antigens. Additional studies have demonstrated that the pANCA human monoclonal antibody (mAb) Fab 5–3 reacts with histone H1 and with bacterial and mycobacterial antigens. Several reports have suggested that, in CD, pANCA and ASCA are correlated with colonic and small bowel disease respectively. One study found that higher ASCA levels were correlated with more aggressive CD. Serology may prove to be useful in predicting the evolution of indeterminate colitis. Magnetic resonance imaging (MRI) and leukocyte scintigraphy hold promise in identifying inflammatory CD. MRI enteroclysis is useful in identifying both luminal small bowel disease and extraluminal complications. A recent study of surveillance colonoscopy in extensive Crohn’s colitis showed a high risk of dysplasia and cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rutgeerts P, Vermeire S: Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. Gastroenterology 1998, 115:1006–1009.

    Article  PubMed  CAS  Google Scholar 

  2. Targan SR, Landers CJ, Cobb L, et al.: Perinuclear antineutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients. J Immunol 1995, 155:3262–3267.

    PubMed  CAS  Google Scholar 

  3. Saxon A, Shanahan F, Landers C, et al.: A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990, 86:202–210.

    Article  PubMed  CAS  Google Scholar 

  4. Roozendaal C, Kallenberg CG: Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Clin Exp Immunol 1999, 116:206–213.

    Article  PubMed  CAS  Google Scholar 

  5. Vidrich A, Lee J, James E, et al.: Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995, 15:293–299.

    Article  PubMed  CAS  Google Scholar 

  6. Billing P, Tahir S, Calfin B, et al.: Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol 1995, 147:979–987.

    PubMed  CAS  Google Scholar 

  7. Sobajima J, Ozaki S, Osakada F, et al.: Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2. Clin Exp Immunol 1997, 107:135–140.

    Article  PubMed  CAS  Google Scholar 

  8. Sobajima J, Ozaki S, Uesugi H, et al.: Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC). Clin Exp Immunol 1998, 111:402–407.

    Article  PubMed  CAS  Google Scholar 

  9. Terjung B, Herzog V, Worman HJ, et al.: Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998, 28:332–340.

    Article  PubMed  CAS  Google Scholar 

  10. Terjung B, Spengler U, Sauerbruch T, Worman HJ: ‘Atypical p-ANCA’ in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000, 119:310–322. These elegant studies demonstrate that pANCA in UC, PSC, and AIH react with a nuclear envelope protein present in neutrophils and two myeloid cell lines. This protein likely resides within the nuclear lamina.

    Article  PubMed  CAS  Google Scholar 

  11. Eggena M, Cohavy O, Parseghian MH, et al.: Identification of histone H1 as a cognate antigen of the ulcerative colitisassociated marker antibody pANCA. J Autoimmun 2000, 14:83–97. The pANCA mAb Fab 5–3 recognizes histone H1.

    Article  PubMed  CAS  Google Scholar 

  12. Mizoguchi E, Mizoguchi A, Chiba C, et al.: Antineutrophil cytoplasmic antibodies in T-cell receptor alpha-deficient mice with chronic colitis. Gastroenterology 1997, 113:1828–1835.

    Article  PubMed  CAS  Google Scholar 

  13. Seibold F, Brandwein S, Simpson S, et al.: pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 1998, 18:153–160.

    Article  PubMed  CAS  Google Scholar 

  14. Cohavy O, Harth G, Horwitz M, et al.: Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn’s disease. Infect Immun 1999, 67:6510–6517.

    PubMed  CAS  Google Scholar 

  15. Cohavy O, Bruckner D, Gordon LK, et al.: Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000, 68:1542–1548. These two studies demonstrate that the pANCA mAb Fab 5–3 recognizes antigens on Mycobacterium species, E. coli, and B. caccae.

    Article  PubMed  CAS  Google Scholar 

  16. Wei B, Dalwadi HN, Gordon LK, et al.: Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody [abstract]. Gastroenterology 2001, 120:A519.

    Article  Google Scholar 

  17. Main J, McKenzie H, Yeaman GR, et al.: Antibody to Saccharomyces cerevisiae (baker’s yeast) in Crohn’s disease. BMJ 1988, 297:1105–1106.

    Article  PubMed  CAS  Google Scholar 

  18. McKenzie H, Main J, Pennington CR, Parratt D: Antibody to selected strains of Saccharomyces cerevisiae (baker’s and brewer’s yeast) and Candida albicans in Crohn’s disease. Gut 1990, 31:536–538.

    PubMed  CAS  Google Scholar 

  19. Sendid B, Colombel JF, Jacquinot PM, et al.: Specific antibody response to oligomannosidic epitopes in Crohn’s disease. Clin Diagn Lab Immunol 1996, 3:219–226.

    PubMed  CAS  Google Scholar 

  20. Seibold F, Ruettten C, Scheurlen M, Goeke B: T cell response to mannans of Saccharomyces cerevisiae in inflammatory bowel disease [abstract]. Gastroenterology 2000, 118:A352.

    Google Scholar 

  21. Peeters M, Joossens S, Vermeire S, et al.: Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001, 96:730–734. The largest study to date of pANCA and ASCA test characteristics. Also contains data on a group of patients with IC.

    Article  PubMed  CAS  Google Scholar 

  22. Vasiliauskas EA, Plevy SE, Landers CJ, et al.: Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup. Gastroenterology 1996, 110:1810–1819.

    Article  PubMed  CAS  Google Scholar 

  23. Satsangi J, Landers CJ, Welsh KI, et al.: The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis 1998, 4:18–26.

    Article  PubMed  CAS  Google Scholar 

  24. Jamar-Leclerc N, Reumaux D, Duthilleul P, Colombel JF: Do pANCA define a clinical subgroup in patients with Crohn’s disease? Gastroenterology 1997, 112:316–317.

    Article  PubMed  CAS  Google Scholar 

  25. Quinton JF, Sendid B, Reumaux D, et al.: Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998, 42:788–791.

    Article  PubMed  CAS  Google Scholar 

  26. Koutroubakis IE, Petinaki E, Mouzas IA, et al.: Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2001, 96:449–454.

    PubMed  CAS  Google Scholar 

  27. VasiliauskasEA, Kam LY, Karp LC, et al.: Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000, 47:487–496. This large study suggests that pANCA and ASCA titers stratify CD into clinical subgroups with distinct disease distribution and aggressiveness.

    Article  PubMed  CAS  Google Scholar 

  28. Taylor KD, Plevy SE, Yang H, et al.: ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 2001, 120:1347–1355.

    Article  PubMed  CAS  Google Scholar 

  29. Vermeire S, Joossens S, Peeters M, et al.: ASCA and pANCA do not predict response to anti-TNFa (Remicade) treatment [abstract]. Gastroenterology 2000, 118:A570.

    Google Scholar 

  30. Bitton A, Peppercorn MA, Antonioli DA, et al.: Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13–20.

    Article  PubMed  CAS  Google Scholar 

  31. Joossens S, Cassagnou M, Vermeire S, et al.: Are anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) useful in indeterminate colitis? A prospective follow-up study [abstract]. Gastroenterology 2000, 118:A886.

    Article  Google Scholar 

  32. Sutton CL, Yang H, Li Z, et al.: Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn’s disease. Gut 2000, 46:58–63. This study shows that ASCA status is a familial trait that may be genetically determined.

    Article  PubMed  CAS  Google Scholar 

  33. Vermeire S, Peeters M, Vlietinck R, et al.: Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001, 7:8–15.

    Article  PubMed  CAS  Google Scholar 

  34. Hugot JP, Chamaillard M, Zouali H, et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001, 411:599–603.

    Article  PubMed  CAS  Google Scholar 

  35. Ogura Y, Bonen DK, Inohara N, et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001, 411:603–606.

    Article  PubMed  CAS  Google Scholar 

  36. Vermeire S, Joossens S, Peeters M, et al.: Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001, 120:827–833. Different ASCA assays have large variations in sensitivity.

    Article  PubMed  CAS  Google Scholar 

  37. Dubinsky MC, Ofman JJ, Urman M, et al.: Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001, 96:758–765.

    Article  PubMed  CAS  Google Scholar 

  38. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR: Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995, 90:740–747.

    PubMed  CAS  Google Scholar 

  39. Fleshner PR, Vasiliauskas EA, Kam LY, et al.: High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch anal anastomosis [abstract]. Gastroenterology 1999, 116:A716.

    Google Scholar 

  40. Panaccione R, Sandborn WJ, Tremaine WJ, et al.: pANCA is associated with chronic pouchitis and predicts the future occurrence of acute pouchitis following ileal pouch-anal anastomosis (IPAA) [abstract]. Gastroenterology 1999, 116:A791.

    Article  Google Scholar 

  41. Charron M: Pediatric inflammatory bowel disease imaged with Tc-99m white blood cells. Clin Nucl Med 2000, 25:708–715.

    Article  PubMed  CAS  Google Scholar 

  42. Molnar T, Papos M, Gyulai C, et al.: Clinical value of technetium-99m-HMPAO-labeled leukocyte scintigraphy and spiral computed tomography in active Crohn’s disease. Am J Gastroenterol 2001, 96:1517–1521.

    PubMed  CAS  Google Scholar 

  43. Charron M, Di Lorenzo C, Kocoshis S: Are 99mTc leukocyte scintigraphy and SBFT studies useful in children suspected of having inflammatory bowel disease? Am J Gastroenterol 2000, 95:1208–1212.

    Article  PubMed  CAS  Google Scholar 

  44. Davison SM, Chapman S, Murphy MS: 99mTc-HMPAO leucocyte scintigraphy fails to detect Crohn’s disease in the proximal gastrointestinal tract. Arch Dis Child 2001, 85:43–46.

    Article  PubMed  CAS  Google Scholar 

  45. Maccioni F, Viscido A, Broglia L, et al.: Evaluation of Crohn disease activity with magnetic resonance imaging. Abdom Imaging 2000, 25:219–228.

    Article  PubMed  CAS  Google Scholar 

  46. Low RN, Francis IR, Politoske D, Bennett M: Crohn’s disease evaluation: comparison of contrast-enhanced MR imaging and single-phase helical CT scanning. J Magn Reson Imaging 2000, 11:127–135.

    Article  PubMed  CAS  Google Scholar 

  47. Rieber A, Wruk D, Potthast S, et al.: Diagnostic imaging in Crohn’s disease: comparison of magnetic resonance imaging and conventional imaging methods. Int J Colorectal Dis 2000, 15:176–181.

    Article  PubMed  CAS  Google Scholar 

  48. Umschaden HW, Szolar D, Gasser J, et al.: H: Small-bowel disease: comparison of MR enteroclysis images with conventional enteroclysis and surgical findings. Radiology 2000, 215:717–725.

    PubMed  CAS  Google Scholar 

  49. D‘Arienzo A, Scaglione G, Vicinanza G, et al.: Magnetic resonance imaging with ferumoxil, a negative superparamagnetic oral contrast agent, in the evaluation of ulcerative colitis. Am J Gastroenterol 2000, 95:720–724.

    Article  PubMed  CAS  Google Scholar 

  50. Ludwig D, Wiener S, Bruning A, et al.: Mesenteric blood flow is related to disease activity and risk of relapse in Crohn’s disease: a prospective follow-up study. Am J Gastroenterol 1999, 94:2942–2950.

    Article  PubMed  CAS  Google Scholar 

  51. Ludwig D, Wiener S, Bruning A, et al.: Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study. Gut 1999, 45:546–552.

    Article  PubMed  CAS  Google Scholar 

  52. Tarjan Z, Toth G, Gyorke T, et al.: Ultrasound in Crohn’s disease of the small bowel. Eur J Radiol 2000, 35:176–182.

    Article  PubMed  CAS  Google Scholar 

  53. Skehan SJ, Issenman R, Mernagh J, et al.: 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. Lancet 1999, 354:836–837.

    PubMed  CAS  Google Scholar 

  54. Bicik I, Bauerfeind P, Breitbach T, et al.: Inflammatory bowel disease activity measured by positron-emission tomography. Lancet 1997, 350:262.

    Article  PubMed  CAS  Google Scholar 

  55. Kurahara K, Matsumoto T, Iida M, et al.: Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced colonic ulcerations. Am J Gastroenterol 2001, 96:473–480.

    Article  PubMed  CAS  Google Scholar 

  56. Cottone M, Pietrosi G, Martorana G, et al.: Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. Am J Gastroenterol 2001, 96:773–775. CMV infection can complicate chronic colitis and cause severe, pseudo-steroid-refractory disease.

    Article  PubMed  CAS  Google Scholar 

  57. Imperiali G, Meucci G, Alvisi C, et al.: Segmental colitis associated with diverticula: a prospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol 2000, 95:1014–1016.

    Article  PubMed  CAS  Google Scholar 

  58. Eaden J, Abrams K, Ekbom A, et al.: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000, 14:145–153.

    Article  PubMed  CAS  Google Scholar 

  59. Heuschen UA, Hinz U, Allemeyer EH, et al.: Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001, 120:841–847. Report from the first study to suggest that backwash ileitis is a marker of increased colon cancer risk in UC.

    Article  PubMed  CAS  Google Scholar 

  60. Friedman S, Rubin PH, Bodian C, et al.: Screening and surveillance colonoscopy in chronic Crohn’s colitis. Gastroenterology 2001, 120:820–826. This report is from a study of colonoscopic surveillance of 259 patients with chronic extensive Crohn’s colitis. Dysplasia or cancer was detected in 12%.

    Article  PubMed  CAS  Google Scholar 

  61. Engelsgjerd M, Farraye FA, Odze RD: Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999, 117:1288–1294.

    Article  PubMed  CAS  Google Scholar 

  62. Rubin PH, Friedman S, Harpaz N, et al.: Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999, 117:1295–1300.

    Article  PubMed  CAS  Google Scholar 

  63. Eaden JA, Ward BA, Mayberry JF: How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 2000, 51:123–128.

    Article  PubMed  CAS  Google Scholar 

  64. Thompson-Fawcett MW, Rust NA, Warren BF, Mortensen NJ: Aneuploidy and columnar cuff surveillance after stapled ileal pouch-anal anastomosis in ulcerative colitis. Dis Colon Rectum 2000, 43:408–413.

    Article  PubMed  CAS  Google Scholar 

  65. O‘Riordain MG, Fazio VW, Lavery IC, et al.: Incidence and natural history of dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of a five-year to ten-year follow-up. Dis Colon Rectum 2000, 43:1660–1665.

    Article  PubMed  CAS  Google Scholar 

  66. Veress B, Reinholt FP, Lindquist K, et al.: Long-term histomorphological surveillance of the pelvic ileal pouch: dysplasia develops in a subgroup of patients. Gastroenterology 1995, 109:1090–1097.

    Article  PubMed  CAS  Google Scholar 

  67. Gullberg K, Stahlberg D, Liljeqvist L, et al.: Neoplastic transformation of the pelvic pouch mucosa in patients with ulcerative colitis. Gastroenterology 1997, 112:1487–1492.

    Article  PubMed  CAS  Google Scholar 

  68. Sarigol S, Wyllie R, Gramlich T, et al.: Incidence of dysplasia in pelvic pouches in pediatric patients after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr 1999, 28:429–434.

    Article  PubMed  CAS  Google Scholar 

  69. Ettorre GM, Pescatori M, Panis Y, et al.: Mucosal changes in ileal pouches after restorative proctocolectomy for ulcerative and Crohn’s colitis. Dis Colon Rectum 2000, 43:1743–1748.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Meyerhoff Inflammatory Bowel Disease Center, Johns Hopkins University, 600 North Wolfe Street/Blalock 463, 21287, Baltimore, MD, USA

    Themistocles Dassopoulos MD

Authors
  1. Themistocles Dassopoulos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dassopoulos, T. Diagnostic methodologies: serology, endoscopy, and radiology. Curr Gastroenterol Rep 3, 491–499 (2001). https://doi.org/10.1007/s11894-001-0070-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-001-0070-z

Keywords

Search

Navigation